Search
Butabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawnButabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates. … [A19735] Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613]
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.
International brands: Ea TenEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … Eculizumab is a monoclonal antibody that targets complement protein C5.
Nebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Products: Nebivolol 1A Pharma 5 mg - TablettenCetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Categories: Compounds used in a research, industrial, or household settingNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingEA-230
go.drugbank.com/drugs/DB19114InvestigationalEA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).
XR5944
go.drugbank.com/drugs/DB06364ExperimentalXR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Finasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigational[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects.
Products: Sandoz Finasteride A, FINASTERID 1A PHARMA 5MGProteasome subunit alpha type-6
go.drugbank.com/bio_entities/BE0003915TargetHumansComponent of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)
Synonyms: Multicatalytic endopeptidase complex iota chain